|
1
|
Knoll S, Fürst K, Kowtharapu B, Schmitz U,
Marquardt S, Wolkenhauer O, Martin H and Pützer BM: E2F1 induces
miR-224/452 expression to drive EMT through TXNIP downregulation.
EMBO Rep. 15:1315–1329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al BRIM-3 Study Group, : Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berrocal A, Cabañas L, Espinosa E,
Fernández-de-Misa R, Martín-Algarra S, Martínez-Cedres JC,
Ríos-Buceta L and Rodríguez-Peralto JL: Melanoma: Diagnosis,
staging, and treatment. Consensus group recommendations. Adv Ther.
31:945–960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Hara SP, Mott JL, Splinter PL, Gores GJ
and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional
gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang R, Guo Y, Ma Z, Ma G, Xue Q, Li F
and Liu L: Long non-coding RNA PTENP1 functions as a ceRNA to
modulate PTEN level by decoying miR-106b and miR-93 in gastric
cancer. Oncotarget. 8:26079–26089. 2017.PubMed/NCBI
|
|
9
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ:
miR-106b promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. World J Gastroenterol.
22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi N, Park J, Lee JS, Yoe J, Park GY,
Kim E, Jeon H, Cho YM, Roh TY and Lee Y:
miR-93/miR-106b/miR-375-CIC-CRABP1: A novel regulatory axis in
prostate cancer progression. Oncotarget. 6:23533–23547. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith AL, Iwanaga R, Drasin DJ, Micalizzi
DS, Vartuli RL, Tan AC and Ford HL: The miR-106b-25 cluster targets
Smad7, activates TGF-β signaling, and induces EMT and tumor
initiating cell characteristics downstream of Six1 in human breast
cancer. Oncogene. 31:5162–5171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prasad R and Katiyar SK: Down-regulation
of miRNA-106b inhibits growth of melanoma cells by promoting
G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1
protein. Oncotarget. 5:10636–10649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin N, Zhou Y, Lian X and Tu Y: Expression
of microRNA-106b and its clinical significance in cutaneous
melanoma. Genet Mol Res. 14:16379–16385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin Y and Shen WH: PTEN: A new guardian of
the genome. Oncogene. 27:5443–5453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu T, Liu L, Li J, Yan M, Lin H, Liu Y,
Chu D, Tu H, Gu A and Yao M: MiRNA-10a is upregulated in NSCLC and
may promote cancer by targeting PTEN. Oncotarget. 6:30239–30250.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li KK, Xia T, Ma FM, Zhang R, Mao Y, Wang
Y, Zhou L, Lau KM and Ng HK: miR-106b is overexpressed in
medulloblastomas and interacts directly with PTEN. Neuropathol Appl
Neurobiol. 41:145–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y,
Yuan L, Zhang C, Hong M, Wang S and Li X: MiR-106b induces cell
radioresistance via the PTEN/PI3K/AKT pathways and p21 in
colorectal cancer. J Transl Med. 13:2522015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soares AS, Costa VM, Diniz C and Fresco P:
Inosine strongly enhances proliferation of human C32 melanoma cells
through PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways. Basic Clin
Pharmacol Toxicol. 116:25–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bouali S, Chrétien AS, Ramacci C, Rouyer
M, Becuwe P and Merlin JL: PTEN expression controls cellular
response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK
downstream signaling in KRAS wild-type, hormone refractory prostate
cancer cells. Oncol Rep. 21:731–735. 2009.PubMed/NCBI
|
|
20
|
Chetram MA and Hinton CV: PTEN regulation
of ERK1/2 signaling in cancer. J Recept Signal Transduct Res.
32:190–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shao J, Li S, Palmqvist L, Fogelstrand L,
Wei SY, Busayavalasa K, Liu K and Liu VM: p27(KIP1) and PTEN
cooperate in myeloproliferative neoplasm tumor suppression in mice.
Exp Hematol Oncol. 5:172016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Macdonald FH, Yao D, Quinn JA and
Greenhalgh DA: PTEN ablation in Ras(Ha)/Fos skin carcinogenesis
invokes p53-dependent p21 to delay conversion while p53-independent
p21 limits progression via cyclin D1/E2 inhibition. Oncogene.
33:4132–4143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beg MS, Brenner AJ, Sachdev J, Borad M,
Kang YK, Stoudemire J, Smith S, Bader AG, Kim S and Hong DS: Phase
I study of MRX34, a liposomal miR-34a mimic, administered twice
weekly in patients with advanced solid tumors. Invest New Drugs.
35:180–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wen MM: Getting miRNA Therapeutics into
the target cells for neurodegenerative diseases: A mini-review.
Front Mol Neurosci. 9:1292016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng R, Pan L, Gao J, Ye X, Chen L, Zhang
X, Tang W and Zheng W: Prognostic value of miR-106b expression in
breast cancer patients. J Surg Res. 195:158–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X,
Ding Q, Zha X, Sha J and Wang S: Downregulation of miR-106b induced
breast cancer cell invasion and motility in association with
overexpression of matrix metalloproteinase 2. Cancer Sci.
105:18–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang A, Hao J, Wang K, Huang Q, Yu K,
Kang C, Wang G, Jia Z, Han L and Pu P: Down-regulation of miR-106b
suppresses the growth of human glioma cells. J Neurooncol.
112:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Tan W, Neo TW, Aung MO, Wasser S,
Lim SG and Tan TM: Role of the miR-106b-25 microRNA cluster in
hepatocellular carcinoma. Cancer Sci. 100:1234–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kan T, Sato F, Ito T, Matsumura N, David
S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, et al: The
miR-106b-25 polycistron, activated by genomic amplification,
functions as an oncogene by suppressing p21 and Bim.
Gastroenterology. 136:1689–1700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong P, Kaneuchi M, Watari H, Sudo S and
Sakuragi N: MicroRNA-106b modulates epithelial-mesenchymal
transition by targeting TWIST1 in invasive endometrial cancer cell
lines. Mol Carcinog. 53:349–359. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiang W, He J, Huang C, Chen L, Tao D, Wu
X, Wang M, Luo G, Xiao X, Zeng F, et al: miR-106b-5p targets tumor
suppressor gene SETD2 to inactive its function in clear cell renal
cell carcinoma. Oncotarget. 6:4066–4079. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ivanovska I, Ball AS, Diaz RL, Magnus JF,
Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson
AL, et al: MicroRNAs in the miR-106b family regulate p21/CDKN1A and
promote cell cycle progression. Mol Cell Biol. 28:2167–2174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhatt KV, Spofford LS, Aram G, McMullen M,
Pumiglia K and Aplin AE: Adhesion control of cyclin D1 and p27Kip1
levels is deregulated in melanoma cells through BRAF-MEK-ERK
signaling. Oncogene. 24:3459–3471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jonason JH, Gavrilova N, Wu M, Zhang H and
Sun H: Regulation of SCF(SKP2) ubiquitin E3 ligase assembly and
p27(KIP1) proteolysis by the PTEN pathway and cyclin D1. Cell
Cycle. 6:951–961. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao L, Pan TJ, Wu GJ, Shen GQ, Yang JR,
Wen HD, Xie S and Qian WH: Effects of adenovirus-mediated PTEN on
the proliferation of prostate cancer PC-3 cells and expressions of
cyclin D1 and p21. Zhonghua Nan Ke Xue. 20:207–212. 2014.(In
Chinese). PubMed/NCBI
|
|
37
|
Jian B, Li Z, Xiao D, He G, Bai L and Yang
Q: Downregulation of microRNA-193-3p inhibits tumor proliferation
migration and chemoresistance in human gastric cancer by regulating
PTEN gene. Tumour Biol. 37:8941–8949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong Y, Richards JA, Gupta R, Aung PP,
Emley A, Kluger Y, Dogra SK, Mahalingam M and Wajapeyee N: PTEN
functions as a melanoma tumor suppressor by promoting host immune
response. Oncogene. 33:4632–4642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yari K, Payandeh M and Rahimi Z:
Association of the hypermethylation status of PTEN tumor suppressor
gene with the risk of breast cancer among Kurdish population from
Western Iran. Tumour Biol. 37:8145–8152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang S, Bian H, Li X, Wu H, Bi Q, Yan Y
and Wang Y: Hydrogen sulfide promotes cell proliferation of oral
cancer through activation of the COX2/AKT/ERK1/2 axis. Oncol Rep.
35:2825–2832. 2016. View Article : Google Scholar : PubMed/NCBI
|
